New data presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress of the investigational ...

FDA clearance allows Imviva to test CTA313, an off-the-shelf CAR T-cell therapy, in progressive MS and other autoimmune ...

Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory ...

Weekly subcutaneous injections of the novel B-cell inhibitor obexelimab significantly reduces disease flares and lowers toxic ...

FDA approval of the B-cell depleting monoclonal antibody inebilizumab-cdon (Uplizna) a year ago for immunoglobulin (Ig)G4-related disease (RD) has cemented B-cell depletion as current first-line ...

In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...

Autoimmune diseases represent a major global health burden, affecting an estimated 4.5% of the world’s population. Their economic impact is also substantial, including a projected cost of US$180 ...

Detailed price information for Sana Biotechnology Inc (SANA-Q) from The Globe and Mail including charting and trades.